NEW YORK (GenomeWeb News) — Pharmacogenomics test developer MolecularMD has reeled in $3 million in financing from the Ballast Point Ventures, according to the St. Petersburg, Fla.-based venture capital firm.

MolecularMD is focused on developing molecular diagnostic tests to speed clinical development and regulatory approval of cancer therapies. The company's first tests were associated with imatinib (Gleevec), Novartis' treatment for chronic myelogenous leukemia, and it plans to expand into other cancer areas, including colon and lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.